52
Participants
Start Date
January 8, 2020
Primary Completion Date
December 31, 2029
Study Completion Date
December 31, 2039
CD33CART autologous
"The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by autologous CD33CART infusion:~LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).~Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable."
CD33CART allogeneic
"The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by allogeneic CD33CART infusion:~LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).~Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable."
The Children's Hospital of Philadelphia, Philadelphia
National Cancer Institute - NIH, Bethesda
Children's Hospital of Colorado, Aurora
Children's Hospital of Los Angeles, Los Angeles
Seattle Children's Hospital/Fred Hutchinson Cancer Research Center, Seattle
Dana-Farber Cancer Institute, Boston
National Marrow Donor Program
OTHER
St. Baldrick's Foundation
OTHER
Center for International Blood and Marrow Transplant Research
NETWORK